Antituberculosis therapy for 2012 and beyond

Expert Opinion on Pharmacotherapy

Volumn 13, Issue 4, 2012, Pages 511-526

  Lauzardo, Michael ^a   Peloquin, Charles A ^a,b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

AZD 5847; Levofloxacin; Moxifloxacin; Multidrug resistant tuberculosis; OPC 67683; PA 824; PNU 100480; Rifampin; Rifapentine; SQ109; TMC207; Tuberculosis

Indexed keywords

6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; AMIKACIN; AMINOSALICYLIC ACID; AMOXICILLIN PLUS CLAVULANIC ACID; AZD 5847; BEDAQUILINE; CAPREOMYCIN; CIPROFLOXACIN; CLARITHROMYCIN; CYCLOSERINE; DELAMANID; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; LINEZOLID; LL 3858; MOXIFLOXACIN; N (2 ADAMANTYL) N' GERANYLETHYLENEDIAMINE; OFLOXACIN; PYRAZINAMIDE; RIFABUTIN; RIFAMPICIN; RIFAPENTINE; STREPTOMYCIN; SUTEZOLID; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ARTHRALGIA; BACTERICIDAL ACTIVITY; BONE MARROW SUPPRESSION; DRUG DISTRIBUTION; DRUG HALF LIFE; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HEPATITIS; HUMAN; LUNG TUBERCULOSIS; MAXIMUM PLASMA CONCENTRATION; MULTIDRUG RESISTANT TUBERCULOSIS; NONHUMAN; OPTIC NERVE DISEASE; PERIPHERAL NEUROPATHY; QT PROLONGATION; REVIEW; TREATMENT DURATION; TUBERCULOSIS; TUBERCULOSIS CONTROL; UVEITIS;

ANIMALS; ANTITUBERCULAR AGENTS; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84857256968     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2012.657176     Document Type: Review

References (95)

1. Camus A. The Plague, Trans. Stuart Gilbert. Modern Library; New York, NY: 1948
2. Manosuthi W, Sungkanuparph S, Tantanathip P, et al. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study. Clin Infect Dis 2009;48(12):1752-9
3. La Porte CJL, Colbers EPH, Bertz R, et al. Pharmacokinetics of adjusted-dose lopinavir-ritonavir combined with rifampin in healthy volunteers. Antimicrob Agents Chemother 2004;48:1553-60 (Pubitemid 38544359)
4. McIlleron H, Meintjes G, Burman WJ, Maartens G. Complications of antiretroviral therapy in patients with tuberculosis: drug interactions, toxicity, and immune reconstitution inflammatory syndrome. J Infect Dis 2007;196(Suppl 1):S63-75 (Pubitemid 47206086)
5. Harries AD, Zachariah R, Corbett EL, et al. The HIV-associated tuberculosis epidemic-when will we act? Lancet 2010;375(9729):1906-19
6. Combs DL, O'Brien RJ, Geiter LJ. USPHS tuberculosis short-course chemotherapy trial 21: effectiveness, toxicity, and acceptability. Ann Intern Med 1990;112(6):397-406 (Pubitemid 20098520)
7. Cohn DL, Catlin BJ, Peterson KL, et al. A 62-Dose, 6-Month therapy for pulmonary and extrapulmonary tuberculosis. Ann Intern Med 1990;112(6):407-15
8. Wells C. Global Impact of multidrug-resistant pulmonary tuberculosis among HIV-infected and other immunocompromised hosts: epidemiology, diagnosis, and strategies for management. Curr Infect Dis Rep 2010;12(3):192-7
9. Tam CM, Chan SL, Lam CW, et al. Rifapentine and isoniazid in the continuation phase of treating pulmonary tuberculosis. Initial report. Am J Respir Crit Care 1998;157(6):1726
10. Vernon A, Burman W, Benator D, et al. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Lancet 1999;353(9167):1843-7 (Pubitemid 29251017)
11. Keshavjee S, Farmer PE. Time to put boots on the ground: making universal access to MDR-TB treatment a reality [Editorial]. Int J Tuberc Lung Dis 2010;14(10):1222-5
12. Gardner CA, Acharya T, Pablos-Mendez A. The Global alliance for tuberculosis drug development-accomplishments and future directions. Clin Chest Med 2005;26(2):341-7
13. Kaufmann SHE. Future vaccination strategies against tuberculosis: thinking outside the box. Immunity 2010;33(4):567-77
14. Hotez PJ, Kamath A. Neglected tropical diseases in sub-Saharan Africa: review of their prevalence, distribution, and disease burden. PLoS Negl Trop Dis 2009;3(8):e412
15. Telenti A, Imboden P, Marchesi F, et al. Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet 1993;341(8846):647-51
16. Dickinson JM, Mitchison DA. Experimental models to explain the high sterilizing activity of rifampin in the chemotherapy of tuberculosis. Am Rev Respir Dis 1981;123(4 Pt 1):367
17. Jindani A, Dore CJ, Mitchison DA. Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days. Am J Respir Crit Care 2003;167(10):1348
18. Fox W, Ellard GA, Mitchison DA. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946 - 1986, with relevant subsequent publications. Int J Tuberc Lung Dis 1999;3(10s2):S231-79 (Pubitemid 29481843)
19. Verbist L, Gyselen A. Antituberculous activity of rifampin in vitro and in vivo and the concentrations attained in human blood. Am Rev Respir Dis 1968;98(6):923
20. Diacon AH, Patientia RF, Venter A, et al. Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears. Antimicrob agents Chemother 2007;51(8):2994-6 (Pubitemid 47206244)
21. Decroix G, Kreis B, Sors C, et al. Comparison between regimes of rifampicin-isoniazid administered daily and administered twice a week (initial results of a comparative study conducted in 4 medical services of the Parisian region). Rev Tuberc Pneumol 1969;33(6):751
22. Kreis B, Pretet S, Birenbaum J, et al. Two three-month treatment regimens for pulmonary tuberculosis. Bull Int Union Tuberc Lung Dis 1976;51(1):71
23. Goutelle S, Bourguignon L, Maire PH, et al. Population modeling and monte carlo simulation study of the pharmacokinetics and antituberculosis pharmacodynamics of rifampin in lungs. Antimicrob Agents Chemother 2009;53(7):2974
24. Steingart KR, Jotblad S, Robsky K, et al. Higher-dose rifampin for the treatment of pulmonary tuberculosis: a systematic review [Review article]. Int J Tuberc Lung Dis 2011;15(3):305-16
25. Boeree J. Global clinical trials for the treatment of TB with thioridazine. Recent Patent Antiinfect Drug Discov 2011;6(2):99-103
26. Burman WJ, Gallicano K, Peloquin C. Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials. Clin Pharmacokinet 2001;40(5):327-41 (Pubitemid 32565595)
27. Sterling TR, Villarino ME, Borisov AS, et al. Three months of rifapentine and isoniazid for treatment of latent tuberculosis infection. N Engl J Med 2011;365:2155-66
28. Skinner MH, Blaschke TF. Clinical pharmacokinetics of rifabutin. Clin Pharmacokinet 1995;28(2):115-25
29. Sacchettini JC, Rubin EJ, Freundlich JS. Drugs versus bugs: in pursuit of the persistent predator mycobacterium tuberculosis. Nat Rev Microbiol 2008;6(1):41-52 (Pubitemid 350286219)
30. Andries K, Verhasselt P, Guillemont J, et al. A diarylquinoline drug active on the ATP synthase of mycobacterium tuberculosis. Science 2005;307(5707):223
31. Koul A, Dendouga N, Vergauwen K, et al. Diarylquinolines target subunit c of mycobacterial ATP synthase. Nat Chem Biol 2007;3(6):323-4 (Pubitemid 46789271)
32. Lounis N, Gevers T, Van Den Berg J, Andries K. Impact of the interaction of R207910 with rifampin on the treatment of tuberculosis studied in the mouse model. Antimicrob Agents Chemother 2008;52(10):3568
33. Sanchez OD, Palomo JB, Ortega MS, Ribas FM. Prudent use of antibiotics and suggestions for improvement from community and hospital pharmacy. Enferm Infecc Microbiol Clin 2010;28(Suppl 4):36-9
34. Ibrahim M, Andries K, Lounis N, et al. Synergistic activity of R207910 combined with pyrazinamide against murine tuberculosis. Antimicrob Agents Chemother 2007;51(3):1011
35. Nuermberger EL, Spigelman MK, Yew WW. Current development and future prospects in chemotherapy of tuberculosis. Respirology 2010;15(5):764-78
36. Nuermberger E. Novel TMC207-containing regimens have sterilizing activity in murine tuberculosis. Presented at ICAAC; 17 - 20 September 2011; Chicago, IL
37. Diacon AH, Pym A, Grobusch M, et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med 2009;360(23):2397-405
38. Shi R, Sugawara I. Development of new anti-tuberculosis drug candidates. Tohoku J Exp Med 2010;221(2):97-106
39. Ashtekar DR, Costa-Perira R, Nagrajan K, et al. In vitro and in vivo activities of the nitroimidazole CGI 17341 against mycobacterium tuberculosis. Antimicrob Agents Chemother 1993;37(2):183
40. Stover CK, Warrener P, VanDevanter DR, et al. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 2000;405(6789):962-6 (Pubitemid 30435054)
41. Singh R, Manjunatha U, Boshoff HIM, et al. PA-824 kills nonreplicating mycobacterium tuberculosis by intracellular NO release. Science 2008;322(5906):1392
42. Maroz A, Shinde SS, Franzblau SG, et al. Release of nitrite from the antitubercular nitroimidazole drug PA-824 and analogues upon one-electron reduction in protic, non-aqueous solvent. Org Biomol Chem 2009;8(2):413-18
43. Lenaerts AJ, Gruppo V, Marietta KS, et al. Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models. Antimicrob Agents Chemother 2005;49(6):2294
44. Tyagi S, Nuermberger E, Yoshimatsu T, et al. Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis. Antimicrob Agents Chemother 2005;49(6):2289
45. Nuermberger E, Rosenthal I, Tyagi S, et al. Combination chemotherapy with the nitroimidazopyran PA-824 and first-line drugs in a murine model of tuberculosis. Antimicrob Agents Chemother 2006;50(8):2621
46. Nuermberger E, Tyagi S, Tasneen R, et al. Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin and pyrazinamide in the murine model of tuberculosis. Antimicrob Agents Chemother 2008;524:1522-4 (Pubitemid 351522025)
47. Diacon AH, Dawson R, Hanekom M, et al. Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients. Int J Tuberc Lung Dis 2011;15(7):949-54
48. Ginsberg AM, Laurenzi MW, Rouse DJ, et al. Safety, tolerability, and pharmacokinetics of PA-824 in healthy subjects. Antimicrob Agents Chemother 2009;53(9):3720
49. Hu Y, Coates ARM, Mitchison DA. Comparison of the sterilising activities of the nitroimidazopyran PA-824 and moxifloxacin against persisting Mycobacterium tuberculosis. Int J Tuberc Lung Dis 2008;12(1):69-73
50. Mitnick CD, McGee B, Peloquin CA. Tuberculosis pharmacotherapy: strategies to optimize patient care. Expert Opin Pharmacother 2009;10:381-401
51. Matsumoto M, Hashizume H, Tomishige T, et al. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med 2006;3(11):e466
52. Yew WW, Lange C, Leung CC. Treatment of tuberculosis: update 2010. Eur Respir J 2011;37(2):441
53. Van Den Boogaard J, Kibiki GS, Kisanga ER, et al. New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development. Antimicrob Agents Chemother 2009;53(3):849
54. Hurdle JG, Lee RB, Budha NR, et al. A microbiological assessment of novel nitrofuranylamides as anti-tuberculosis agents. J Antimicrob Chemother 2008 Nov;62(5):1037-45
55. Protopopova M, Hanrahan C, Nikonenko B, et al. Identification of a new antitubercular drug candidate, SQ109, from a combinatorial library of 1, 2-ethylenediamines. J Antimicrob Chemother 2005;56(5):968
56. Spigelman M, Gillespie S. Tuberculosis drug development pipeline: progress and hope. Lancet 2006;367(9514):945-7
57. Chen P, Gearhart J, Protopopova M, et al. Synergistic interactions of SQ109, a new ethylene diamine, with front-line antitubercular drugs in vitro. J Antimicrob Chemother 2006;58(2):332
58. Jia L, Tomaszewski JE, Hanrahan C, et al. Pharmacodynamics and pharmacokinetics of SQ109, a new diamine based antitubercular drug. Br J Pharmacol 2005;144(1):80-7 (Pubitemid 40192564)
59. Jia L, Coward L, Gorman GS, et al. Pharmacoproteomic effects of isoniazid, ethambutol, and N-geranyl-N -(2- adamantyl) ethane-1, 2-diamine (SQ109) on Mycobacterium tuberculosis H37Rv. J Pharmacol Exp Ther 2005;315(2):905
60. Jia L, Tomaszewski JE, Noker PE, et al. Simultaneous estimation of pharmacokinetic properties in mice of three anti-tubercular ethambutol analogs obtained from combinatorial lead optimization. J Pharm Biomed Anal 2005;37(4):793-9 (Pubitemid 40417755)
61. Nikonenko BV, Protopopova M, Samala R, et al. Drug therapy of experimental TB: improved outcome by combining SQ109, new diamine antibiotic, with existing TB drugs. Antimicrob Agents Chemother 2007;51:1563-5 (Pubitemid 46586854)
62. Reddy VM, Einck L, Andries K, Nacy CA. In vitro interactions between new antitubercular drug candidates SQ109 and TMC207. Antimicrob Agents Chemother 2010;54(7):2840
63. Louw GE. Rifampicin reduces susceptibility to Ofloxacin in Rifampicin-resistant mycobacterium tuberculosis through efflux. Am J Respir Crit Care Med 2011;184:269-76
64. Sequella Licenses Rights to Commercialize SQ109 for Tuberculosis in Russia to Maxwell Biotech Venture Fund Subsidiary. Available from http:// online.wsj.com/article/PR-CO-20110425- 900011.html Accessed January 2012
65. Rodriguez JC, Ruiz M, Lopez M, Royo G. In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis. Int J Antimicrob Agents 2002;20(6):464-7 (Pubitemid 35379989)
66. Fortun J, Martin-Davila P, Navas E, et al. Linezolid for the treatment of multidrug-resistant tuberculosis. J Antimicrob Chemother 2005;56(1):180
67. Ntziora F, Falagas ME. Linezolid for the treatment of patients with atypical mycobacterial infection: a systematic review [Review Article]. Int J Tuberc Lung Dis 2007;11(6):606-11 (Pubitemid 46868619)
68. Von der Lippe B, Sandven P, Brubakk O. Efficacy and safety of linezolid in multidrug resistant tuberculosis (MDR-TB): a report of ten cases. J Infect 2006;52(2):92-6 (Pubitemid 43137390)
69. French G. Safety and tolerability of linezolid. J Antimicrob Chemother 2003;51(Suppl 2):ii45
70. Nam H-S, Koh W-J, Kwon OJ, et al. Daily half-dose linezolid for the treatment of intractable multidrug-resistant tuberculosis. Int J Antimicrob Agents 2009;33(1):92-3
71. Park IN, Hong S-B, Oh Y-M, et al. Efficacy and tolerability of daily-half dose linezolid in patients with intractable multidrug-resistant tuberculosis. J Antimicrob Chemother 2006;58(3):701-4 (Pubitemid 44288145)
72. Cynamon MH, Klemens SP, Sharpe CA, Chase S. Activities of several novel oxazolidinones against Mycobacterium tuberculosis in a murine model. Antimicrob Agents Chemother 1999;43(5):1189
73. Williams KN, Stover CK, Zhu T, et al. Promising antituberculosis activity of the oxazolidinone PNU-100480 relative to that of linezolid in a murine model. Antimicrob Agents Chemother 2009;53(4):1314
74. Wallis RS, Jakubiec WM, Kumar V, et al. Pharmacokinetics and whole-blood bactericidal activity against Mycobacterium tuberculosis of single doses of PNU-100480 in healthy volunteers. J Infect Dis 2010;202(5):745
75. Alffenaar JWC, van der Laan T, Simons S, et al. Susceptibility of clinical mycobacterium tuberculosis isolates to a potentially less toxic derivate of linezolid, PNU-100480. Antimicrob Agents Chemother 2011;55(3):1287
76. Arora S. Eradication of mycobacterium tuberculosis infection in 2 months with LL-3858: a preclinical study. Int J Tuberc Lung Dis 2004;8(11 Suppl 1):S29
77. Shindikar AV, Viswanathan CL. Novel fluoroquinolones: design, synthesis, and in vivo activity in mice against Mycobacterium tuberculosis H37Rv. Bioorg Med Chem 2005;15(7):1803-6 (Pubitemid 40380736)
78. Garcia-Rodriguez JA, Garcia AC. In-vitro activities of quinolones against mycobacteria. J Antimicrob Chemother 1993;32(6):797
79. Rastogi N, Goh KS. In vitro activity of the new difluorinated quinolone sparfloxacin (AT-4140) against Mycobacterium tuberculosis compared with activities of ofloxacin and ciprofloxacin. Antimicrob Agents Chemother 1991;35(9):1933
80. Paramasivan CN, Sulochana S, Kubendiran G, et al. Bactericidal action of gatifloxacin, rifampin, and isoniazid on logarithmic- and stationary-phase cultures of mycobacterium tuberculosis. Antimicrob Agents Chemother 2005;49(2):627-31 (Pubitemid 40175672)
81. Nuermberger EL, Yoshimatsu T, Tyagi S, et al. Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis. Am J Respir Crit Care Med 2004;169(3):421
82. Nuermberger EL, Yoshimatsu T, Tyagi S, et al. Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis. Am J Respir Crit Care Med 2004;170(10):1131-4 (Pubitemid 39488628)
83. Pletz MWR, De Roux A, Roth A, et al. Early bactericidal activity of moxifloxacin in treatment of pulmonary tuberculosis: a Prospective, Randomized Study. Antimicrob Agents Chemother 2004;48(3):780-2 (Pubitemid 38280324)
84. Johnson JL, Hadad DJ, Boom WH, et al. Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 2006;6(10):605-12 (Pubitemid 43845020)
85. Burman WJ, Goldberg S, Johnson JL, et al. Moxifloxacin versus ethambutol in the first two months of treatment for pulmonary tuberculosis. Am J Respir Crit Care Med 2006;174(3):331-8 (Pubitemid 44156613)
86. Conde MB, Efron A, Loredo C, et al. Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial. Lancet 2009;373(9670):1183-9
87. Rustomjee R, Lienhardt C, Kanyok T, et al. A phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 2008;12(2):128-38 (Pubitemid 351212403)
88. Tasneen R, Li SY, Peloquin CA, et al. Sterilizing activity of novel TMC207-and PA-824-containing regimens in a murine model of tuberculosis. Antimicrob Agents Chemother 2011;55:5485-92
89. Van Deun A, Maug AKJ, Salim MAH, et al. Short, highly effective and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2010;182:684-92
90. Aubry A, Veziris N, Cambau E, et al. Novel gyrase mutations in quinolone-resistant and hypersusceptible clinical isolates of mycobacterium tuberculosis: functional analysis of mutant enzymes. Antimicrob Agents Chemother 2006;50(1):104
91. Veziris N, Martin C, Brossier F, et al. Treatment failure in a case of extensively drug-resistant tuberculosis associated with selection of a GyrB mutant causing fluoroquinolone resistance. Eur J Clin Microbiol Infect Dis 2007;26(6):423-5 (Pubitemid 46872994)
92. Devasia RA, Blackman A, Gebretsadik T, et al. Fluoroquinolone resistance in Mycobacterium tuberculosis: the effect of duration and timing of fluoroquinolone exposure. Am J Respir Crit Care Med 2009;180(4):365
93. Verma U, Sharma R, Gupta P, et al. New uses for old drugs: novel therapeutic options. Indian J Pharmacol 2005;37(5):279
94. Drusano GL, Sgambati N, Eichas A, et al. Effect of administration of moxifloxacin plus rifampin against mycobacterium tuberculosis for 7 of 7 days versus 5 of 7 days in an in vitro pharmacodynamic system. mBio 2011;2(4):e00108-11
95. Park-Wyllie LY, Juurlink DN, Kopp A, et al. Outpatient gatifloxacin therapy and dysglycemia in older adults. N Engl J Med 2006;354(13):1352-61